Belite Bio Q3 net loss widens on higher R&D expenses

Reuters

11/10

<a href="https://laohu8.com/S/BLTE">Belite Bio</a> Q3 net loss widens on higher R&D expenses

Overview

Belite Bio reports Q3 net loss of $21.7 mln, increased from $8.7 mln last year
Company completed $15 mln direct offering and $125 mln private placement
China's NMPA and UK's MHRA accept Tinlarebant applications based on DRAGON trial

Outlook

Company expects final DRAGON trial data in Q4 2025
Company anticipates interim analysis for PHOENIX trial
Company aims for regulatory milestones with Tinlarebant

Result Drivers

INCREASED R&D EXPENSES - Driven by costs associated with DRAGON and PHOENIX trials, partially offset by Australian R&D tax incentive
FINANCIAL STRENGTHENING - Completion of $15 mln direct offering and $125 mln private placement enhances financial position

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Net Income		-$21.69 mln
Q3 Income From Operations		-$23.02 mln
Q3 Operating Expenses		$23.02 mln
Q3 Pretax Profit		-$21.69 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Belite Bio Inc is $104.00, about 8.8% below its November 7 closing price of $113.19

Press Release: ID:nGNX4z2RCs

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2582871382"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2582871382\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2582871382?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-10 21:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582871382","market":"us","top_or_hot":-1,"title":"Belite Bio Q3 net loss widens on higher R&D expenses","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/BLTE\">Belite Bio</a> Q3 net loss widens on higher R&amp;D expenses </title></head><body><p><span>Overview</span></p><ul><li><p>Belite Bio reports Q3 net loss of $21.7 mln, increased from $8.7 mln last year</p></li><li><p>Company completed $15 mln direct offering and $125 mln private placement</p></li><li><p>China's NMPA and UK's MHRA accept Tinlarebant applications based on DRAGON trial</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company expects final DRAGON trial data in Q4 2025</p></li><li><p>Company anticipates interim analysis for PHOENIX trial</p></li><li><p>Company aims for regulatory milestones with Tinlarebant</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>INCREASED R&amp;D EXPENSES - Driven by costs associated with DRAGON and PHOENIX trials, partially offset by Australian R&amp;D tax incentive</p></li><li><p>FINANCIAL STRENGTHENING - Completion of $15 mln direct offering and $125 mln private placement enhances financial position</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$21.69 mln</p></td><td></td></tr><tr><td><p>Q3 Income From Operations</p></td><td></td><td><p>-$23.02 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$23.02 mln</p></td><td></td></tr><tr><td><p>Q3 Pretax Profit</p></td><td></td><td><p>-$21.69 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 5 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Belite Bio Inc is $104.00, about 8.8% below its November 7 closing price of $113.19</p></li></ul><p>Press Release: <span>ID:nGNX4z2RCs</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Belite Bio Q3 net loss widens on higher R&D expenses</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBelite Bio Q3 net loss widens on higher R&D expenses\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-11-10 21:12</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/BLTE\">Belite Bio</a> Q3 net loss widens on higher R&amp;D expenses </title></head><body><p><span>Overview</span></p><ul><li><p>Belite Bio reports Q3 net loss of $21.7 mln, increased from $8.7 mln last year</p></li><li><p>Company completed $15 mln direct offering and $125 mln private placement</p></li><li><p>China's NMPA and UK's MHRA accept Tinlarebant applications based on DRAGON trial</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company expects final DRAGON trial data in Q4 2025</p></li><li><p>Company anticipates interim analysis for PHOENIX trial</p></li><li><p>Company aims for regulatory milestones with Tinlarebant</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>INCREASED R&amp;D EXPENSES - Driven by costs associated with DRAGON and PHOENIX trials, partially offset by Australian R&amp;D tax incentive</p></li><li><p>FINANCIAL STRENGTHENING - Completion of $15 mln direct offering and $125 mln private placement enhances financial position</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$21.69 mln</p></td><td></td></tr><tr><td><p>Q3 Income From Operations</p></td><td></td><td><p>-$23.02 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$23.02 mln</p></td><td></td></tr><tr><td><p>Q3 Pretax Profit</p></td><td></td><td><p>-$21.69 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 5 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Belite Bio Inc is $104.00, about 8.8% below its November 7 closing price of $113.19</p></li></ul><p>Press Release: <span>ID:nGNX4z2RCs</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BLTE","symbol_name":"Belite Bio, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nL1N3WM0HS:1","article_id":"2582871382","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582871382","pubTimestamp":1762780322,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Belite Bio Q3 net loss widens on higher R&D expensesOverviewBelite Bio reports Q3 net loss of $21.7 mln, increased from $8.7 mln last yearCompany completed $15 mln direct offering and $125 mln private","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BLTE":"Belite Bio, Inc.","BK4007":"制药"},"translate_title":"贝利特生物第三季度净亏损因研发费用增加而扩大","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BLTE":0.9},"content_text":"Belite Bio Q3 net loss widens on higher R&D expenses OverviewBelite Bio reports Q3 net loss of $21.7 mln, increased from $8.7 mln last yearCompany completed $15 mln direct offering and $125 mln private placementChina's NMPA and UK's MHRA accept Tinlarebant applications based on DRAGON trialOutlookCompany expects final DRAGON trial data in Q4 2025Company anticipates interim analysis for PHOENIX trialCompany aims for regulatory milestones with TinlarebantResult DriversINCREASED R&D EXPENSES - Driven by costs associated with DRAGON and PHOENIX trials, partially offset by Australian R&D tax incentiveFINANCIAL STRENGTHENING - Completion of $15 mln direct offering and $125 mln private placement enhances financial positionKey DetailsMetricBeat/MissActualConsensus EstimateQ3 Net Income-$21.69 mlnQ3 Income From Operations-$23.02 mlnQ3 Operating Expenses$23.02 mlnQ3 Pretax Profit-$21.69 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 5 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy\"Wall Street's median 12-month price target for Belite Bio Inc is $104.00, about 8.8% below its November 7 closing price of $113.19Press Release: ID:nGNX4z2RCsFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}